As suggested by Mantovani et al. (36), given that the risk allele G of PNPLA3 rs738409 is linked to an increased risk of the fibrosis development and progression and that the severity of NAFLD is associated with a worse glycemic control (37, 38), we should not expect the lower glucose and HbA1c levels in the patients who carry the risk allele G of PNPLA3 rs738409. This evidence concerns the gene PNPLA3 and metabolic dysfunction-associated steatotic liver disease.